| D008297 |
Male |
|
Males |
|
| D009733 |
Nursing Diagnosis |
Conclusions derived from the nursing assessment that establish a health status profile for the patient and from which nursing interventions may be ordered. |
Diagnosis, Nursing,Diagnoses, Nursing,Nursing Diagnoses |
|
| D011605 |
Psychoses, Substance-Induced |
Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance. |
Psychoses, Drug,Psychoses, Toxic,Substance-Induced Psychoses,Toxic Psychoses,Drug Psychoses,Psychoses, Substance Induced,Substance Induced Psychoses |
|
| D004305 |
Dose-Response Relationship, Drug |
The relationship between the dose of an administered drug and the response of the organism to the drug. |
Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response |
|
| D004359 |
Drug Therapy, Combination |
Therapy with two or more separate preparations given for a combined effect. |
Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug |
|
| D004409 |
Dyskinesia, Drug-Induced |
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) |
Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias |
|
| D006220 |
Haloperidol |
A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) |
Haldol |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000293 |
Adolescent |
A person 13 to 18 years of age. |
Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths |
|
| D001590 |
Benztropine |
A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine. |
Apo-Benztropine,Bensylate,Benzatropine,Benzatropine Mesylate,Benzatropine Methanesulfonate,Benzatropine Methanesulfonate, Hydrobromide,Benzatropine Methanesulfonate, Hydrobromide, (endo)-Isomer,Benzatropine Methanesulfonate, Hydrochloride, (endo)-Isomer,Benztropine Mesylate,Cogentin,Cogentinol,N-Methylbenztropine,PMS-Benztropine,Apo Benztropine,Hydrobromide Benzatropine Methanesulfonate,Mesylate, Benzatropine,Mesylate, Benztropine,Methanesulfonate, Benzatropine,Methanesulfonate, Hydrobromide Benzatropine,N Methylbenztropine,PMS Benztropine |
|